حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
تاريخ الأرباح AKTX
تحليلات الأرباح AKTX
Max Ratio
–نمو الأرباح على مدى 5 سنوات
–النمو المستمر
–معدل الدفع 5 سنوات في المتوسط
–Akari Therapeutics PLC
AKTXAkari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts. Address: 22 Boston Wharf Road, Boston, MA, United States, 02210
Analytics
سعر الهدف في وول ستريت
7.00 USDنسبة السعر إلى الأرباح
–العائد الربحي
–المالية AKTX
نتائج | 2019 | ديناميات |